TRAJ : Transition in Rheumatology, From Adolescence to Adulthood
Launched by UNIVERSITY HOSPITAL, BORDEAUX · Jul 22, 2025
Trial Information
Current as of November 11, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how well a special support program called CAPAdJA helps young people with chronic rheumatic diseases continue their medical care as they move from child to adult healthcare services. The study will compare how many patients stay in regular follow-up care six months after their transition appointment, between those who used the CAPAdJA program and those who did not. This is important because keeping up with care during this change can be challenging, and the program aims to make it easier.
To take part, patients must have had a transition consultation from pediatric to adult rheumatology care at Bordeaux University Hospital between 2017 and 2024 and be over 18 years old when filling out a questionnaire. The study is open to all genders, but participants need to speak French and agree to join. If you join, you will complete a questionnaire about your healthcare experience after the transition. This study is not yet recruiting, but it hopes to improve how young adults with rheumatic diseases manage their care during this important time.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients who benefited from a pediatric-to-adult rheumatology transition consultation at Bordeaux University Hospital between 2017 and 2024
- • Patients over 18 years old at the time of completing the self-administered questionnaire.
- Exclusion Criteria:
- • Patients who do not speak French
- • Patients who have refused to participating
About University Hospital, Bordeaux
The University Hospital of Bordeaux is a leading academic medical center dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the institution integrates cutting-edge scientific inquiry with patient care, fostering an environment that encourages collaboration among multidisciplinary teams. With a commitment to improving treatment outcomes and enhancing patient safety, the University Hospital of Bordeaux plays a pivotal role in the development of new therapies and medical technologies, contributing significantly to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bordeaux, France
Patients applied
Trial Officials
Olivier RICHER, MD
Principal Investigator
University Hospital, Bordeaux
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported